Synergistic Effect of 3-Bromopyruvate in Combination with Rapamycin Impacted Neuroblastoma Metabolism by Inhibiting Autophagy

Background: Alterations in the cell metabolism, such as enhanced aerobic glycolysis, have been identified as a prominent hallmark of Cancer cells. 3-Bromopyruvate (3-BrPA) is a proverbial Hexokinase (HK)-II inhibitor, which can inhibit Cancer cell energy metabolism. Rapamycin is a new type macrocyclic lactone, which can inhibit the serine/threonine protein kinase mTOR. In order to comprehend the influence of 3-BrPA on Autophagy activity in vitro, we conducted a series of experiments using different human neuroblastoma (NB) cell lines.

Materials and methods: The human NB cell lines were exposed to 3-BrPA and/or rapamycin, and the proliferation activity of the cells was detected by Cell Counting Kit-8 (CCK-8) assay. The mRNA expression of the cells treated with 3-BrPA and/or rapamycin was analyzed by quantitative real-time polymerase chain reaction (QPCR) assay. The protein expression of the cells was analyzed by Western Blotting (WB) assay. The effects of 3-BrPA and/or rapamycin treatment on cell cycle and cell Apoptosis were analyzed by flow cytometry assay. Meanwhile, the cellular glucose absorption rate, lactate secretion rate and ATP content were also analyzed through the relevant metabolic analysis kits.

Results: Our results showed that 3-BrPA can induce growth inhibition in a dose-dependent pattern by cell Apoptosis. 3-BrPA combined with rapamycin played a synergistic suppression role in NB cells, affected the cell Apoptosis, cell cycle and the metabolic pathway. Up-regulated LC3-II accumulation was conscious in NB cells incubated with 3-BrPA and rapamycin. Rapamycin individually discourages the mTOR signaling pathway, while combined with 3-BrPA can enhance this phenomenon and influence cell metabolism of the NB cells.

Conclusion: The results suggested that 3-BrPA combined with rapamycin could induce cell Apoptosis in NB cells by inhibiting mTOR activity. In conclusion, our research proposed that the dual inhibitory effect of the mTOR signaling pathway and the glycolytic activity may indicate a valid therapeutic tactic for NB chemoprevention.